Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miriam Koopman

Showing results (51-60 of 193) with videos related to

Pageof 20
Sort By:
Cancer Epidemiology|October 15, 2018
Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patientsKoen Degeling, Mira D Franken, Anne M May, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2023
Impact of colorectal cancer screening on survival after metachronous metastasisPatricia A H Hamers, Geraldine R Vink, Marloes A G Elferink, et al.
International Journal of Colorectal Disease|April 4, 2021
Disease recurrence after colorectal cancer surgery in the modern era: a population-based studySeyed M Qaderi, Boris Galjart, Cornelis Verhoef, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2024
Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 monthsIngrid A Franken, Frederieke H van der Baan, Geraldine R Vink, et al.
British Journal of Cancer|November 11, 2017
Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trialsKaitlyn K H Goey, Sjoerd G Elias, Axel Hinke, et al.
International Journal of Cancer|August 20, 2019
Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world dataGabrielle Jongeneel, Thomas Klausch, Felice N van Erning, et al.
Plos One|April 18, 2015
EMAST is associated with a poor prognosis in microsatellite instable metastatic colorectal cancerSabine Venderbosch, Shannon van Lent-van Vliet, Anton F J de Haan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 9, 2025
Risk of deficient mismatch repair colorectal cancer and precursors after kidney transplantation: A nationwide studyKoen Zwart, Rob C M van Kruijsdijk, Valentina Angerilli, et al.
The American Journal of Clinical Nutrition|September 14, 2019
Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patientsSophie A Kurk, Rebecca K Stellato, Petra H M Peeters, et al.
Obesity Research & Clinical Practice|September 30, 2023
Effect of adipose tissue quantity and dysfunction on the risk of cancer in individuals with and without type 2 diabetesMarga A G Helmink, Jan Westerink, Steven H J Hageman, et al.
Pageof 20

Showing results (51-60 of 193) with videos related to

Sort By:
Pageof 20
Cancer Epidemiology|October 15, 2018
Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patientsKoen Degeling, Mira D Franken, Anne M May, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2023
Impact of colorectal cancer screening on survival after metachronous metastasisPatricia A H Hamers, Geraldine R Vink, Marloes A G Elferink, et al.
International Journal of Colorectal Disease|April 4, 2021
Disease recurrence after colorectal cancer surgery in the modern era: a population-based studySeyed M Qaderi, Boris Galjart, Cornelis Verhoef, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2024
Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 monthsIngrid A Franken, Frederieke H van der Baan, Geraldine R Vink, et al.
British Journal of Cancer|November 11, 2017
Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trialsKaitlyn K H Goey, Sjoerd G Elias, Axel Hinke, et al.
International Journal of Cancer|August 20, 2019
Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world dataGabrielle Jongeneel, Thomas Klausch, Felice N van Erning, et al.
Plos One|April 18, 2015
EMAST is associated with a poor prognosis in microsatellite instable metastatic colorectal cancerSabine Venderbosch, Shannon van Lent-van Vliet, Anton F J de Haan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 9, 2025
Risk of deficient mismatch repair colorectal cancer and precursors after kidney transplantation: A nationwide studyKoen Zwart, Rob C M van Kruijsdijk, Valentina Angerilli, et al.
The American Journal of Clinical Nutrition|September 14, 2019
Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patientsSophie A Kurk, Rebecca K Stellato, Petra H M Peeters, et al.
Obesity Research & Clinical Practice|September 30, 2023
Effect of adipose tissue quantity and dysfunction on the risk of cancer in individuals with and without type 2 diabetesMarga A G Helmink, Jan Westerink, Steven H J Hageman, et al.
Pageof 20